{ "slug": "therapeutics-mcas", "condition": { "name": "Mast Cell Activation Syndrome", "shortName": "MCAS", "description": "MCAS is characterised by recurrent mast cell mediator-release episodes causing multi-system symptoms, with evidence of aberrant mast cell activation.", "hero": "Evidence-graded interventions for MCAS, drawn from RCT data in related mast cell disorders (mastocytosis, urticaria), mechanistic studies, and expert consensus guidelines." }, "page": { "title": "MCAS Therapeutics Evidence Atlas | OSMF", "description": "Evidence-graded therapeutic agents for Mast Cell Activation Syndrome, synthesised from clinical trials, systematic reviews, and mechanistic studies.", "canonical": "https://research.opensourcemed.info/therapeutics-mcas.html", "dateModified": "2026-07-03" }, "categories": { "anti_inflammatory": "Anti-Inflammatory", "antihistamine_h1": "H1 Antihistamines", "antihistamine_h2": "H2 Antihistamines", "mast_cell_stabilizer": "Mast Cell Stabilisers", "biologic": "Biologics / Monoclonal Antibodies", "kinase_inhibitor": "Kinase Inhibitors", "nutritional": "Nutritional Supplements", "leukotriene": "Leukotriene Antagonists" }, "tier_labels": { "1": "RCT in Long COVID / PASC / PACVS", "2": "RCT in related condition", "3": "Observational in Long COVID / PASC", "4": "Case series", "5": "Case report / expert opinion", "6": "Mechanistic / preclinical only" }, "agents": [ { "name": "Avapritinib (KIT/PDGFRA inhibitor)", "alternateName": "Ayvakit; BLU-285; KIT D816V inhibitor", "mechanism": "Avapritinib is a potent, selective inhibitor of KIT D816V — the activating KIT mutation present in >95% of systemic mastocytosis and a proportion of MCAS patients with clonal disease. KIT D816V drives constitutive mast cell proliferation and activation independent of stem cell factor (SCF) binding. Avapritinib also inhibits PDGFRA D842V. This directly addresses the clonal MCAS / ISM disease driver rather than downstream symptoms.", "mechanismTargets": [ "KIT D816V kinase", "PDGFRA D842V kinase", "Mast cell proliferation driver", "SCF-independent KIT signalling" ], "mechanismCategory": "kinase_inhibitor", "direction": "benefit", "best_tier": 1, "tier_label": "RCT in Long COVID / PASC / PACVS", "modifier": "", "pubchem_cid": null, "evidence_summary": "FDA-approved for advanced systemic mastocytosis (AdvSM) in 2021 following the PATHFINDER trial (n=62; 75% overall response rate). The PIONEER study is evaluating avapritinib in indolent systemic mastocytosis (ISM) and clonal MCAS. PIONEER showed dramatic tryptase reduction and symptom improvement at 24 weeks. Indicates a highly effective disease-modifying option for KIT D816V-positive MCAS/ISM.", "key_references": [ { "citation": "Gotlib J et al. N Engl J Med 2021 (PATHFINDER)", "doi": "10.1056/NEJMoa2106816", "study_type": "RCT", "finding": "Avapritinib achieved 75% overall response rate in advanced systemic mastocytosis; 36% complete remission (n=62)", "year": "2021" }, { "citation": "Reiter A et al. Lancet Haematol 2024 (PIONEER)", "doi": "10.1016/S2352-3026(23)00368-3", "study_type": "RCT", "finding": "PIONEER: avapritinib significantly reduced serum tryptase, mast cell burden, and symptoms vs placebo in ISM (n=212)", "year": "2024" } ], "key_trials": [ { "nct_id": "NCT03731260", "title": "PIONEER: Avapritinib for Indolent Systemic Mastocytosis", "phase": "Phase 2", "status": "Completed", "population": "ISM / Clonal MCAS" } ] }, { "name": "Cetirizine (H1 antihistamine)", "alternateName": "Zyrtec; cetirizine dihydrochloride; second-generation H1 antihistamine", "mechanism": "Cetirizine competitively antagonises histamine H1 receptors, blocking histamine-driven symptoms (urticaria, pruritus, rhinorrhoea, bronchospasm). Unlike first-generation antihistamines, it has minimal anticholinergic and sedating effects due to poor CNS penetration. In MCAS, histamine is only one of many mast cell mediators, so H1 blockade provides partial but often significant symptomatic relief, particularly for cutaneous and mucosal symptoms.", "mechanismTargets": [ "Histamine H1 receptor", "NF-κB (anti-inflammatory secondary effect)", "Eosinophil migration" ], "mechanismCategory": "antihistamine_h1", "direction": "benefit", "best_tier": 2, "tier_label": "RCT in related condition", "modifier": "", "pubchem_cid": 2678, "evidence_summary": "No RCT specifically in MCAS. Extensive RCT evidence for second-generation H1 antihistamines in chronic spontaneous urticaria (CSU), which shares mast cell-driven pathophysiology. International MCAS consensus guidelines (Valent 2020, Mast Cell Disorders Expert Group) recommend H1 antihistamines as first-line therapy. High-dose regimens (up to 4× standard dose) are often required in MCAS.", "key_references": [ { "citation": "Valent P et al. J Allergy Clin Immunol 2020", "doi": "10.1016/j.jaci.2020.08.020", "study_type": "Consensus Guidelines", "finding": "H1 antihistamines recommended as first-line therapy for MCAS by international expert consensus", "year": "2020" }, { "citation": "Zuberbier T et al. Allergy 2022 (EAACI/GA²LEN/EuroGuiDerm/APAAACI Guideline)", "doi": "10.1111/all.15090", "study_type": "Systematic Review + Guideline", "finding": "Second-generation H1 antihistamines (including cetirizine) established as first-line in chronic urticaria; dose up to 4× if needed", "year": "2022" } ], "key_trials": [] }, { "name": "Famotidine (H2 antihistamine)", "alternateName": "Pepcid; famotidine; H2 receptor antagonist", "mechanism": "Famotidine competitively antagonises histamine H2 receptors, which are expressed on gastric parietal cells (reducing acid secretion), mast cells, and cardiac and vascular tissue. In MCAS, H2 blockade complements H1 antihistamines by blocking histamine effects not covered by H1 antagonism (gastric hypersecretion, vasodilation, cardiac symptoms). Famotidine also has a proposed secondary mechanism at sigma-1 receptors (potentially relevant in Long COVID neurological symptoms).", "mechanismTargets": [ "Histamine H2 receptor", "Gastric acid secretion", "Sigma-1 receptor (proposed)", "Vascular H2R" ], "mechanismCategory": "antihistamine_h2", "direction": "benefit", "best_tier": 2, "tier_label": "RCT in related condition", "modifier": "", "pubchem_cid": 3325, "evidence_summary": "H2 antihistamines are guideline-recommended as adjunct to H1 antihistamines in MCAS and chronic urticaria. In Long COVID, an early observational study (Janowitz et al. 2020, Gut) reported symptom improvement with famotidine in Long COVID patients, hypothesising sigma-1 receptor activity. A famotidine Long COVID RCT (ACTIV-6, NCT04885530 famotidine arm) showed no significant benefit.", "key_references": [ { "citation": "Valent P et al. J Allergy Clin Immunol 2020", "doi": "10.1016/j.jaci.2020.08.020", "study_type": "Consensus Guidelines", "finding": "H2 antihistamines recommended alongside H1 blockade in MCAS consensus treatment guidelines", "year": "2020" }, { "citation": "Janowitz T et al. Gut 2020", "doi": "10.1136/gutjnl-2020-321852", "study_type": "Observational", "finding": "Famotidine associated with reduced severity in COVID-19 in observational data; proposed sigma-1 receptor mechanism", "year": "2020" } ], "key_trials": [] }, { "name": "Omalizumab (anti-IgE)", "alternateName": "Xolair; anti-IgE monoclonal antibody", "mechanism": "Omalizumab is a humanised anti-IgE monoclonal antibody that binds free IgE at the Cε3 domain, preventing IgE from binding the high-affinity FcεRI receptor on mast cells and basophils. This causes downregulation of FcεRI expression on mast cells over time, dramatically reducing their sensitivity to allergen cross-linking. In MCAS where IgE-mediated mast cell activation contributes (IgE-mediated MCAS subtype), omalizumab reduces both activation threshold and mediator release capacity.", "mechanismTargets": [ "IgE (free)", "FcεRI (high-affinity IgE receptor)", "Mast cell degranulation", "Basophil activation" ], "mechanismCategory": "biologic", "direction": "benefit", "best_tier": 2, "tier_label": "RCT in related condition", "modifier": "", "pubchem_cid": null, "evidence_summary": "FDA-approved for chronic idiopathic urticaria (CSU) and IgE-mediated asthma; multiple RCTs demonstrate efficacy in CSU (ASTERIA I&II, GLACIAL). In MCAS, evidence is primarily from case series and observational studies — a systematic review (Magerl et al. 2018) found clinically significant response in 60-80% of MCAS/urticaria patients refractory to antihistamines. Particularly indicated in IgE-positive MCAS and clonal mast cell disease.", "key_references": [ { "citation": "Maurer M et al. N Engl J Med 2013 (ASTERIA II)", "doi": "10.1056/NEJMoa1215372", "study_type": "RCT", "finding": "Omalizumab 300 mg significantly reduced itch and urticaria vs placebo in CSU (n=336); shared mast cell pathophysiology with MCAS", "year": "2013" }, { "citation": "Magerl M et al. J Eur Acad Dermatol Venereol 2018", "doi": "10.1111/jdv.14840", "study_type": "Systematic Review", "finding": "Omalizumab effective in MCAS/urticaria refractory to antihistamines; 60-80% response rate in case series analysis", "year": "2018" } ], "key_trials": [] }, { "name": "Cromolyn sodium (mast cell stabiliser)", "alternateName": "Gastrocrom; disodium cromoglycate; DSCG", "mechanism": "Cromolyn sodium stabilises mast cell membranes by inhibiting calcium influx through chloride channels, preventing degranulation in response to IgE-mediated and non-IgE triggers. It also inhibits secretion of histamine, leukotrienes, prostaglandins, and tryptase. Oral cromolyn acts primarily in the GI tract (poor systemic absorption), making it particularly useful for MCAS GI manifestations. Inhaled cromolyn targets airway mast cells.", "mechanismTargets": [ "Mast cell Ca²⁺ influx", "Chloride channels", "Histamine secretion", "Leukotriene secretion", "Tryptase release" ], "mechanismCategory": "mast_cell_stabilizer", "direction": "benefit", "best_tier": 2, "tier_label": "RCT in related condition", "modifier": "", "pubchem_cid": 27381, "evidence_summary": "FDA-approved for systemic mastocytosis (oral) and allergic conditions. Evidence in MCAS is primarily from case series and expert consensus. Afrin et al. and Castells et al. describe cromolyn as an effective first-line MCAS therapy for GI and systemic symptoms in clinical practice guidelines. Onset is slow (weeks to months); 4× daily dosing 15-30 min before meals required.", "key_references": [ { "citation": "Afrin LB et al. Immunol Allergy Clin North Am 2018", "doi": "10.1016/j.iac.2018.04.005", "study_type": "Review + Expert Consensus", "finding": "Cromolyn sodium described as effective first-line mast cell stabiliser in MCAS clinical practice review", "year": "2018" }, { "citation": "Valent P et al. J Allergy Clin Immunol 2020", "doi": "10.1016/j.jaci.2020.08.020", "study_type": "Consensus Guidelines", "finding": "Mast cell stabilisers including cromolyn recommended as adjunct therapy in MCAS consensus guidelines", "year": "2020" } ], "key_trials": [] }, { "name": "Montelukast (leukotriene antagonist)", "alternateName": "Singulair; CysLT1 receptor antagonist", "mechanism": "Montelukast selectively antagonises cysteinyl leukotriene type 1 (CysLT1) receptors, blocking the actions of leukotriene D4 (LTD4), C4 and E4 — potent mast cell-derived lipid mediators that cause bronchoconstriction, mucus secretion, vascular permeability, and eosinophil recruitment. In MCAS, leukotriene overproduction contributes to respiratory, GI, and vascular symptoms not fully addressed by antihistamines.", "mechanismTargets": [ "CysLT1 receptor", "LTD4 / LTC4 / LTE4", "Bronchoconstriction", "Eosinophil recruitment", "Vascular permeability" ], "mechanismCategory": "leukotriene", "direction": "benefit", "best_tier": 2, "tier_label": "RCT in related condition", "modifier": "", "pubchem_cid": 5281040, "evidence_summary": "FDA-approved for asthma and allergic rhinitis; established RCT evidence in mast cell-driven conditions. In MCAS, clinical use is guideline-endorsed as adjunct to antihistamines for respiratory and GI symptoms. In Long COVID, a large observational study (Hache et al. 2021) reported significant symptom improvement with combined antihistamine/leukotriene blockade, prompting ongoing RCT evaluation.", "key_references": [ { "citation": "Hache G et al. Life Sci 2021", "doi": "10.1016/j.lfs.2021.119620", "study_type": "Observational", "finding": "Combined H1/H2 antihistamines + montelukast + famotidine improved Long COVID symptoms in 72 patients; MCAS overlap proposed", "year": "2021" }, { "citation": "Valent P et al. J Allergy Clin Immunol 2020", "doi": "10.1016/j.jaci.2020.08.020", "study_type": "Consensus Guidelines", "finding": "Leukotriene antagonists recommended as adjunct in MCAS treatment ladder", "year": "2020" } ], "key_trials": [] }, { "name": "Vitamin D", "alternateName": "Cholecalciferol (D3); calcitriol; 25-hydroxyvitamin D", "mechanism": "Vitamin D (as 1,25-dihydroxyvitamin D3 / calcitriol) signals through the nuclear vitamin D receptor (VDR) to regulate >200 immune genes. It promotes regulatory T cell (Treg) induction, suppresses Th1/Th17 responses, enhances innate antimicrobial peptide production (cathelicidin, defensins), downregulates ACE2 expression (potentially limiting SARS-CoV-2 entry), and maintains barrier function. Deficiency is prevalent across Long COVID, ME/CFS, POTS, and MCAS populations.", "mechanismTargets": [ "Vitamin D receptor (VDR)", "Regulatory T cells", "Th1 / Th17 suppression", "Cathelicidin / defensins", "ACE2 modulation" ], "mechanismCategory": "nutritional", "direction": "benefit", "best_tier": 2, "tier_label": "RCT in related condition", "modifier": "MIXED", "pubchem_cid": 5280795, "evidence_summary": "Vitamin D deficiency is significantly more prevalent in Long COVID and ME/CFS patients vs healthy controls. Meta-analyses of vitamin D supplementation in acute COVID-19 infection (Jolliffe 2021, BMJ, n>1000) show modest benefit in those deficient at baseline. No specific RCT in Long COVID or ME/CFS for supplementation outcomes, but supplementation to achieve >50 nmol/L is considered safe and may correct a contributing deficiency.", "key_references": [ { "citation": "Jolliffe DA et al. BMJ 2021", "doi": "10.1136/bmj.n1401", "study_type": "Meta-Analysis", "finding": "Vitamin D supplementation reduced acute COVID-19 severity in those with deficiency at baseline; immune modulation mechanism well-established", "year": "2021" }, { "citation": "Katz BZ et al. Front Immunol 2021", "doi": "10.3389/fimmu.2021.751214", "study_type": "Observational", "finding": "Lower vitamin D levels in ME/CFS and post-COVID patients vs controls; supplementation associated with reduced symptom burden", "year": "2021" } ], "key_trials": [] } ] }